404 related articles for article (PubMed ID: 32589269)
21. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
22. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.
Thabet K; Asimakopoulos A; Shojaei M; Romero-Gomez M; Mangia A; Irving WL; Berg T; Dore GJ; Grønbæk H; Sheridan D; Abate ML; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Spengler U; Nattermann J; Wahid A; Rojas A; White R; Douglas MW; McLeod D; Powell E; Liddle C; van der Poorten D; George J; Eslam M;
Nat Commun; 2016 Sep; 7():12757. PubMed ID: 27630043
[TBL] [Abstract][Full Text] [Related]
23. Association of MBOAT7 gene variant with plasma ALT levels in children: the PANIC study.
Viitasalo A; Eloranta AM; Atalay M; Romeo S; Pihlajamäki J; Lakka TA
Pediatr Res; 2016 Nov; 80(5):651-655. PubMed ID: 27411039
[TBL] [Abstract][Full Text] [Related]
24. The Health Impact of MAFLD, a Novel Disease Cluster of NAFLD, Is Amplified by the Integrated Effect of Fatty Liver Disease-Related Genetic Variants.
Liu Z; Suo C; Shi O; Lin C; Zhao R; Yuan H; Jin L; Zhang T; Chen X
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e855-e875. PubMed ID: 33387670
[TBL] [Abstract][Full Text] [Related]
25. Obesity-linked suppression of membrane-bound
Helsley RN; Varadharajan V; Brown AL; Gromovsky AD; Schugar RC; Ramachandiran I; Fung K; Kabbany MN; Banerjee R; Neumann CK; Finney C; Pathak P; Orabi D; Osborn LJ; Massey W; Zhang R; Kadam A; Sansbury BE; Pan C; Sacks J; Lee RG; Crooke RM; Graham MJ; Lemieux ME; Gogonea V; Kirwan JP; Allende DS; Civelek M; Fox PL; Rudel LL; Lusis AJ; Spite M; Brown JM
Elife; 2019 Oct; 8():. PubMed ID: 31621579
[TBL] [Abstract][Full Text] [Related]
26. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
28. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
[TBL] [Abstract][Full Text] [Related]
29. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
30. Lack of evidence supporting a role of TMC4-rs641738 missense variant-MBOAT7- intergenic downstream variant-in the Susceptibility to Nonalcoholic Fatty Liver Disease.
Sookoian S; Flichman D; Garaycoechea ME; Gazzi C; Martino JS; Castaño GO; Pirola CJ
Sci Rep; 2018 Mar; 8(1):5097. PubMed ID: 29572551
[TBL] [Abstract][Full Text] [Related]
31. MBOAT7 in liver and extrahepatic diseases.
Caddeo A; Spagnuolo R; Maurotti S
Liver Int; 2023 Nov; 43(11):2351-2364. PubMed ID: 37605540
[TBL] [Abstract][Full Text] [Related]
32. Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria.
Kolawole OJ; Oje MM; Betiku OA; Ijarotimi O; Adekanle O; Ndububa DA
BMC Gastroenterol; 2024 May; 24(1):147. PubMed ID: 38724942
[TBL] [Abstract][Full Text] [Related]
33. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent.
Palmer ND; Musani SK; Yerges-Armstrong LM; Feitosa MF; Bielak LF; Hernaez R; Kahali B; Carr JJ; Harris TB; Jhun MA; Kardia SL; Langefeld CD; Mosley TH; Norris JM; Smith AV; Taylor HA; Wagenknecht LE; Liu J; Borecki IB; Peyser PA; Speliotes EK
Hepatology; 2013 Sep; 58(3):966-75. PubMed ID: 23564467
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
35. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
36. Effects of MBOAT7 polymorphism and steatosis on liver function assessed by methacetin breath test.
Di Ciaula A; Bonfrate L; Shanmugam H; Weber SN; Krawczyk M; Portincasa P
Eur J Clin Invest; 2023 Aug; 53(8):e14003. PubMed ID: 37029745
[TBL] [Abstract][Full Text] [Related]
37. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.
Luukkonen PK; Zhou Y; Hyötyläinen T; Leivonen M; Arola J; Orho-Melander M; Orešič M; Yki-Järvinen H
J Hepatol; 2016 Dec; 65(6):1263-1265. PubMed ID: 27520876
[No Abstract] [Full Text] [Related]
38. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
39.
Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875804
[TBL] [Abstract][Full Text] [Related]
40. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
Bianco C; Jamialahmadi O; Pelusi S; Baselli G; Dongiovanni P; Zanoni I; Santoro L; Maier S; Liguori A; Meroni M; Borroni V; D'Ambrosio R; Spagnuolo R; Alisi A; Federico A; Bugianesi E; Petta S; Miele L; Vespasiani-Gentilucci U; Anstee QM; Stickel F; Hampe J; Fischer J; Berg T; Fracanzani AL; Soardo G; Reeves H; Prati D; Romeo S; Valenti L
J Hepatol; 2021 Apr; 74(4):775-782. PubMed ID: 33248170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]